Search ASX code:
Generic filters

Search ASX code:
Generic filters

Search ASX code:
Generic filters

Want to invest ethically for a brighter future?
(but still make lots of money)?

Want to invest ethically for a brighter future? (but still make lots of money)?

 Take Rask’s FREE Ethical Investing course today.

  • Online & 100% free
  • ETFs, shares & Super
Want to invest ethically for a brighter future? 
(but still make lots of money)?

 Take Rask’s FREE online Ethical Investing course.

Will COVID vaccine troubles hurt the CSL (ASX:CSL) share price?

There’s a question mark about over the CSL Limited (ASX: CSL) share price with ongoing troubles with the COVID-19 vaccines.

What has happened with CSL and vaccines?

CSL hasn’t had much luck with its involvement with COVID-19 vaccines. The local vaccine hopeful, the University of Queensland, was cancelled because the UQ vaccine was bringing up false positives when it came to HIV tests.

There are now questions marks about the AstraZeneca plc (LON: AZN) COVID-19 vaccine because of concerns relating to rare blood clots. Due to this, the UK government’s joint committee on vaccines and immunisation (JCVI) said that adults under 30 will be offered an alternative, because the reward – risk ratio is not as great as it is for older adults.

At this stage the Australian government hasn’t made any decisions, but it’s reviewing the findings of the UK and European regulators.

Australia has been struggling to get any external supply of COVID-19 vaccines, with the jabs being in high demand in countries that are being ravaged by the pandemic in the northern hemisphere. The major hope is that CSL can manufacture millions of the AstraZeneca vaccine locally and then the country wouldn’t be reliant on imports.

But the blood clotting news, as well as potentially lower effectiveness compared to other vaccines, could cause some difficulties for CSL. Some Australian states have blamed the federal government for the lack of progress with vaccinations being rolled out.

Should investors worry about the CSL share price?

The vaccination manufacturing is important task for CSL, but it’s not the only source of earnings. The biotech company is a healthcare giant, it generates huge amounts of earnings for from its other products such as non-COVID vaccinations and biotherapies.

CSL’s role in society is very important. We all want to stay alive and healthy. That’s why CSL invests around 10% of its revenue each year into research and development (R&D) to make new products and help people.

Whilst the AZ vaccine may be struggling a bit, the other vaccines will help CSL’s plasma operations in the US get back to a new normal. The weakness of the CSL share price over the last few months could prove to be a long term buy opportunity. However, there are other ASX growth shares that may be able to generate stronger returns thanks to their smaller size.

Is BNPL the opportunity of a lifetime or is the sector a ticking time bomb?

Rask's analyst has just finished a 7,500-word report, The Ultimate BNPL Sector Report, taking a deep dive into this booming ASX sector. It shines a spotlight on each of the major players. You can get the full analyst report for FREE by CLICKING HERE NOW or entering your email below.

Note: the report is 100% free.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Afterpay, Zip Co, Sezzle…

Is BNPL the opportunity of a lifetime or is the sector a ticking time bomb?

Rask's analyst has just finished a 7,500-word report, The Ultimate BNPL Sector Report, taking a deep dive into this booming ASX sector. It shines a spotlight on each of the major players. You can get the full analyst report for FREE by CLICKING HERE NOW.

Note: the report is 100% free.

At the time of publishing, the author of this article does not have a financial or commercial interest in any of the companies mentioned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Keep reading:

Rask Media’s Ultimate BNPL Sector Report

Afterpay, Zip, Sezzle… is this the opportunity of a lifetime? Or is BNPL a ticking time bomb? This 7,500-word analyst report takes a deep dive into the BNPL sector and shines a spotlight on each of the major players in this booming market. 

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

As we emerge from COVID-19, some tech companies are growing faster than ever. Rask’s investment analysts have identified 3 growth stocks set to benefit. Big time.

Enter your email below to access this report for free, including the names, ticker codes and analysis.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.